AC
CRSP icon

AXQ Capital’s CRISPR Therapeutics CRSP Stock Holding History

AXQ Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$525K Buy
+9,634
New +$508K 0.06% 470
2024
Q1 		– Sell
-3,875
Closed -$243K – 665
2023
Q4 		$243K Buy
+3,875
New +$214K 0.06% 453

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AXQ Capital's CRSP Position: Q2 2026 in Review

AXQ Capital opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 9,634 shares worth $525K. The stake represents 0.06% of the portfolio and ranks #470 among its holdings. This is a return to the name: AXQ Capital previously reported a position in CRSP as recently as Q4 2023.

AXQ Capital first reported a position in CRSP in Q4 2023 and has held it in 2 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • AXQ Capital held 9,634 shares of CRISPR Therapeutics worth $525K as of Q2 2026.
  • CRISPR Therapeutics was a new AXQ Capital position in Q2 2026.
  • CRISPR Therapeutics made up 0.06% of AXQ Capital's portfolio in Q2 2026, its #470 holding.
  • AXQ Capital first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 2 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.